


## CLAIMS

1. Compound of formula (I):



5

in which

X represents N or CH;


R<sub>1</sub> represents a hydrogen or halogen atom or a CF<sub>3</sub> group;

- 10 R<sub>2</sub> and R<sub>3</sub> independently represent a hydrogen atom or a methyl group;


n is 0 or 1;

W represents a diazoheterocycle of formula (a) to (d)

15




(a)



(b)




(c)




(d)

A represents a group of formula (e) or (f)



(e)



(f)

where

$R_4$  represents a hydrogen or halogen atom, a  
 5 (C<sub>1</sub>-C<sub>4</sub>)alkyl group, a CF<sub>3</sub> group, an amino, a  
 mono(C<sub>1</sub>-C<sub>4</sub>)alkylamino or a di(C<sub>1</sub>-C<sub>4</sub>)alkylamino  
 group;

$R_5$  represents a hydrogen or halogen atom, a  
 (C<sub>1</sub>-C<sub>4</sub>)alkoxy group, a (C<sub>1</sub>-C<sub>4</sub>)alkyl group or a  
 10 CF<sub>3</sub> group;

$R_6$  represents a hydrogen atom, a (C<sub>1</sub>-C<sub>4</sub>)alkyl  
 group or a (C<sub>1</sub>-C<sub>4</sub>)alkoxy group;

it being possible for only one or both of the atoms of  
 the rings (a) to (d) to be oxidized;

15 and their salts or solvates.

2. Compound according to Claim 1, where n  
 is zero.

3. Compound according to Claim 1 or 2,  
 where  $R_2$  and  $R_3$  are each a hydrogen atom.

20 4. Compound according to Claim 1 or 2,  
 where  $R_1$  is a CF<sub>3</sub> group.

5. Compound according to Claim 1 or 2,  
 where  $R_1$  is a fluorine or chlorine atom.


6. Compound according to Claims 1 to 3,  
where X is CH and R<sub>1</sub> is at the 3-position of the  
benzene.

7. Compound according to Claims 1 to 3,  
5 where X is CH and R<sub>1</sub> is at the 2-position of the  
benzene.

8. Compound according to Claims 1 to 3,  
where X is N and the pyridine is substituted at the  
2,6-positions.


10 9. Compound according to Claims 1 to 8,  
chosen from its mono-N-oxide derivatives, its bis-N-  
oxides and its tri-N-oxides.

10. Method for preparing the compound of  
Claim 1, characterized in that there are carried out a  
15 condensation/reduction reaction of a compound of  
formula (II):



in which X, W and R<sub>1</sub> are as defined in Claim 1, with an  
aldehyde of formula (III):


20



in which R<sub>2</sub>, R<sub>3</sub>, n and A are as defined above, the  
isolation of the compound of formula (I) and the

optional conversion to one of its salts or solvates or to its N-oxide derivatives.

11. Compound of formula (II')



in which W represents a group of formula (b) or (c) according to Claim 1, and its salts or solvates.

12. Pharmaceutical composition containing, as active ingredient, a compound of formula (I)

10 according to Claims 1 to 9 or one of its pharmaceutically acceptable salts or solvates.

13. Composition according to Claim 12, characterized in that it contains from 0.001 to 100 mg of active ingredient.

15 14. Use of a compound of formula (I) according to Claims 1 to 9 or of one of its pharmaceutically acceptable salts or solvates for the preparation of analgesic medicaments and/or intended for the treatment of diseases linked to immune and  
20 inflammatory disorders.

15. Medicament comprising, as active ingredient, a compound of formula (I) according to Claims 1 to 9 or one of its pharmaceutically acceptable salts or solvates.